Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Arnatar Biomedical Raises $15 Million in Seed Round for RNAi Therapies

publication date: Sep 19, 2022

Arnatar Biomedical, a Shanghai-San Diego startup, raised nearly $15 million in a Seed Round led by Shanghai’s Apricot Investment. The company is developing its advanced antisense technology program to modulate the expression of target RNA with programable potency, onset and duration of action using RNAi and antisense oligonucleotide (ASOs) platforms. Arnatar aims to treat diseases in both liver and extra-hepatic organs for both common and rare disease indications. The company will use the Seed funding to build a unique antisense nucleic acid bidirectional regulation technology platform and to advance the development of several novel candidates. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital